Breaking News, Collaborations & Alliances

ONO, Gilead to Develop BTK Inhibitor

ONO-4059 shows clinical activity in CLL and NHL

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

ONO Pharmaceutical and Gilead Sciences have entered into an exclusive license agreement for the development and commercialization of ONO-4059, ONO’s oral Bruton’s tyrosine kinase (BTK) inhibitor for the treatment of B-cell malignancies and other diseases. ONO will receive an upfront payment plus certain development, regulatory and commercial milestones. The companies will jointly development ONO-4059. Gilead will have exclusive rights to develop and commercialize ONO-4059 in all countries outsi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters